A Perspective from the 'Reimagining Psychedelic Trials' Working Group - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article De Blog Scientifique Année : 2023

A Perspective from the 'Reimagining Psychedelic Trials' Working Group

Tehseen Noorani
  • Fonction : Auteur
Matthew Baggott
  • Fonction : Auteur
Gillinder Bedi
  • Fonction : Auteur
Boris Heifets
  • Fonction : Auteur
Katie Hendy
  • Fonction : Auteur
Nicolas Langlitz
  • Fonction : Auteur
Celia Morgan
  • Fonction : Auteur
Harriet de Wit
  • Fonction : Auteur

Résumé

2022 saw a rise in interdisciplinary groups, events and conferences examining psychedelic research and scholarship. Comprised of scientists, social scientists and humanists, our own ‘Reimagining Psychedelic Trials’ working group began meeting early in the year. Trial design is important to each of us, but for different reasons that speak to the very important but diverse stakes in psychedelic research today. As such, trial design has operated as a boundary object organising our conversations. Over the year, we discussed readings on the topics of placebo, colonialism, regulatory guidelines, psychotherapy, shamanism and real-world evidence. So far, we have sought to better comprehend one another’s approaches, problems, and modes of inquiry. In what follows we will share some of the questions that have emerged in our group over the year.
Fichier non déposé

Dates et versions

hal-04240520 , version 1 (13-10-2023)

Identifiants

  • HAL Id : hal-04240520 , version 1

Citer

Tehseen Noorani, Matthew Baggott, Gillinder Bedi, Boris Heifets, Katie Hendy, et al.. A Perspective from the 'Reimagining Psychedelic Trials' Working Group. 2023. ⟨hal-04240520⟩
21 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More